Lv2
124 积分 2022-12-05 加入
GPCR drug discovery: new agents, targets and indications
4天前
已完结
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
11天前
已完结
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
11天前
已关闭
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
11天前
已关闭
An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD
11天前
已关闭
A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus
14天前
已完结
De novo discovery of cyclic peptide inhibitors of IL-11 signaling
25天前
已完结
Systematical identification of regulatory GPCRs by single-cell trajectory inference reveals the role of ADGRD1 and GPR39 in adipogenesis
1个月前
已完结
Androgen membrane receptor modulates muscle strength
1个月前
已关闭
Identification, structure, and agonist design of an androgen membrane receptor
1个月前
已完结
皖公网安备34019202002308
